Erschienen in:
07.08.2017 | Original Scientific Report
Histologically Proven Bronchial Neuroendocrine Tumors in MEN1: A GTE 51-Case Cohort Study
verfasst von:
P. Lecomte, C. Binquet, M. Le Bras, A. Tabarin, C. Cardot-Bauters, F. Borson-Chazot, C. Lombard-Bohas, E. Baudin, B. Delemer, M. Klein, B. Vergès, T. Aparicio, E. Cosson, A. Beckers, Ph. Caron, O. Chabre, Ph. Chanson, H. Du Boullay, I. Guilhem, P. Niccoli, V. Rohmer, J. Guigay, C. Vulpoi, J. Y. Scoazec, P. Goudet
Erschienen in:
World Journal of Surgery
|
Ausgabe 1/2018
Einloggen, um Zugang zu erhalten
Abstract
Objective
To evaluate the natural history of MEN1-related bronchial endocrine tumors (br-NETs) and to determine their histological characteristics, survival and causes of death.
Summary background data
br-NETs frequency ranges from 3 to 13% and may reach 32% depending on the number of patients evaluated and on the criteria required for diagnosis.
Methods
The 1023-patient series of symptomatic MEN1 patients followed up in a median of 48.7 [35.5–59.6] years by the Groupe d’étude des Tumeurs Endocrines was analyzed using time-to-event techniques.
Results
br-NETs were found in 51 patients (4.8%, [95% CI 3.6–6.2%]) and were discovered by imaging in 86% of cases (CT scan, Octreoscan, Chest X-ray, MRI). Median age at diagnosis was 45 years [28–66]. Histological examination showed 27 (53%) typical carcinoids (TC), 16 (31%) atypical carcinoids (AC), 2 (4%) large cell neuroendocrine carcinomas (LCNEC), 3(6%) small cell neuroendocrine carcinomas (SCLC), 3(6%) TC associated with AC. Overall survival was not different from the rest of the cohort (HR 0.29, [95% CI 0.02–5.14]). AC tended to have a worse prognosis than TC (p = 0.08). Seven deaths were directly related to br-NETs (three AC, three SCLC and one LCNEC). Patients who underwent surgery survived longer (p = 10−4) and were metastasis free, while 8 of 14 non-operated patients were metastatic. There were no operative deaths.
Conclusions
Around 5% of MEN1 patients develop br-NETs. br-NETs do not decrease overall survival in MEN1 patients, but poorly differentiated and aggressive br-NETs can cause death. br-NETs must be screened carefully. A biopsy is essential to operate on patients in time.